You are here

  • Home
  • Archive
  • Volume 6, Issue 1
  • Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Article metrics

Article menu

Download PDFPDF

Review
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

 

Online download statistics by month:

Online download statistics by month: December 2019 to July 2025

AbstractFullPdf
Dec 2019882
Jan 202096964
Feb 202014214211
Mar 202020820829
Apr 202015315321
May 202015015020
Jun 202010410423
Jul 202010910923
Aug 202012712523
Sep 202015515529
Oct 202024524564
Nov 202028128265
Dec 202034734734
Jan 202128728772
Feb 202127927953
Mar 202129929972
Apr 202135035092
May 202137537571
Jun 202133333373
Jul 202127427537
Aug 202123023056
Sep 202131631658
Oct 202128128057
Nov 202130130089
Dec 202123023059
Jan 202230231350
Feb 202223124567
Mar 202233937265
Apr 202224326053
May 202227828868
Jun 202224025656
Jul 202219222058
Aug 202226327150
Sep 202222322831
Oct 202224024559
Nov 202227728169
Dec 202221321445
Jan 202320820948
Feb 202338539280
Mar 202334935446
Apr 202323824444
May 202323123432
Jun 202325725741
Jul 202324524554
Aug 202324124134
Sep 202321121237
Oct 202342442653
Nov 202324624838
Dec 202316916926
Jan 202415515628
Feb 202423323845
Mar 202433734056
Apr 202427427766
May 202418218546
Jun 202422322649
Jul 202421321754
Aug 202415115027
Sep 202415715577
Oct 202421722087
Nov 202419219750
Dec 202423323638
Jan 202517217455
Feb 202544345053
Mar 202521521651
Apr 202520020248
May 202518919072
Jun 202515415635
Jul 2025110
Total15866160883278